Low-dose IL-2 for lupus patients with CMV infection
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study tests if a low dose of IL-2 can help control both lupus and CMV virus in the blood. It aims to see if the treatment improves symptoms and reduces virus levels safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of lupus (SLE) as defined by standard criteria.
- You must have a positive test for CMV virus in your blood.
- You should be between 18 and 65 years old and weigh between 45 and 80 kg.
- You must be taking less than 1.0 mg per kg per day of corticosteroid medication.
- You cannot have other active infections like hepatitis B, C, HIV, or TB.
- You cannot have had a CMV vaccine in the last 6 months, nor IVIG or leflunomide in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment using specially grown immune cells (virus-specific lymphocytes) to fight a stubborn CMV infection that hasn't gotten better with usual medicines. It is for people who have had a stem cell transplant and need help controlling CMV.
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
This Phase 2 study tests a preventive “cell therapy” made from a donor’s immune cells to lower the risk of CMV infection after a haploidentical stem cell transplant. If you’re at risk for CMV, this may help protect you during the early post-transplant period.
This study tests a new medicine, IMC-002, for people with active lupus that hasn't been controlled by standard treatments. It aims to see if the drug can reduce lupus activity and improve symptoms.
This Phase 3 study tests whether interleukin-2 can better control “active” dermatomyositis, an inflammatory muscle and skin disease. Participants will be monitored to see if treatment improves disease activity and symptoms.
Hear when a new SLE (Systemic Lupus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.